Our Research

Dr. David Scott is very active in the field of orthopaedic surgery and joint replacement research. He believes that research is critical to the advancement of medicine and necessary for improving the care and solutions we offer our patients.

Dr. Scott is a leader in the research field and is one of the most active physicians in joint replacement research in the region. He initiates many of his own studies, which is unique among his peers. He recognizes that physician-driven research is critical for finding new and better ways to serve patients. Dr. Scott has a strong team supporting this important research. The full team at OSC maintains certifications with The National Institute of Health and The Collaborative Institutional Training Initiative. In addition, Dr. Scott has been a leader in technology design and continues to help design some of the tools that are shaping orthopaedics today. Some of his work has included development of a state-of-the-art knee replacement system. His commitment to research expands into the academic world and helps shape the future of the profession. He is on the academic staff at both the University of Utah and the University of Washington.

Current Research (Actively Enrolling)

  • Medacta GMK Sphere Medial-Pivot, Cruciate Substituting vs. Medacta GMK PS Posterior Stabilized Knee Outcomes Study. (Click poster to read more.)

    AAOS Poster

  • Medacta GMK Sphere Medial-Pivot, Cruciate Substituting Multi-Center, Post-Market Outcomes Study.
  • Antero-Posterior Knee Stability with Medial-pivot, Cruciate-Substituting, and Posterior-Stabilized Total Knee Arthroplasty.  A Retrospective Study.
  • An Open-Label, Non-Controlled Study to Evaluate Outcomes of Pulsed Electromagnetic Field (PEMF) Therapy in Subjects with Various Pain Etiologies.

Ongoing Studies (Enrollment is Closed)

  • A Prospective Comparison of Total Knee Arthroplasty with the OMNI Apex Ultracongruent vs. the Triathlon CS Tibial Insert vs. the Triathlon PS Tibial Insert. (Click the posters and publications below to read more).

    AAHKS Poster

    AAOS Poster

    Journal of Arthroplasty

  • A DXA Evaluation of Bone Density Changes After Hip Replacement.  Performance of the OMNI Apex Modular Hip Stem and the OMNI Apex Arc Stem in Primary Total Hip Arthroplasty.  Five Year Clinical and DXA Analysis.
  • A Dual Energy X-Ray Absorptiometry Comparison of Periprosthetic Bone Loss Between Patients Undergoing Hip Resurfacing Surgery and Total Hip Arthroplasty.

Past Research Projects

Knee Injection Study

A multi-­centre, parallel, double-blind, blinded evaluator, randomized placebo controlled study to evaluate the safety and effectiveness of a new visco­elastic hydrogel in the treatment of knee osteoarthritis with an open label extension.

Total Knee Replacement Study

A prospective, matched case comparison of total knee arthroplasty in comparison with pain/motion knee society scores of subjects implanted with different knee devices.

Total Hip Replacement Study

A dual energy x-ray absorptiometry (DXA) evaluation of bone density changes after hip replacement. To analyze bone mineral density measurements with the performance of a Modular hip stem vs a novel neck-sparing device in primary total hip arthroplasty.

Hip Resurfacing Study

A dual energy x-ray absorptiometry (DXA) comparison of periprosthetic bone loss between patients undergoing less ­invasive hip resurfacing surgery vs total hip arthroplasty.

Zometa/Reclast Study

This study is being done to determine if Zoledronic Acid (Zometa) is effective in preventing bone loss commonly seen after total hip replacement surgery. Bone mineral density is also being measured at several intervals in the seven gruen zones of the proximal femur by a dual energy x-ray apsorptiometry (DXA). Not enrolling.

Screen Shot 2014-02-26 at 2.34.09 PM

Zoledronic Acid (ZOL) Infusion Reduces Femoral Bone Loss Following Total Hip Arthroplasty (THA)(pdf)

Dual-energy X-ray Absorptiometry (DXA) Study

This study is a long-term ongoing follow-up study. At annual visits after total hip replacement surgery, the patient's bone mineral density is measured to evaluate the general status of their bone density using a spinal and orthopaedic hip DXA scan. This study was initiated by Dr. David Scott.

The Effect Of Risedronate On Femoral Remodeling Following Total Hip Arthroplasty (using dual energy x-ray absorptiometry to measure bone mineral density)

This study is investigating the use of risedronate (Actonel) in reducing bone loss in the femur, which is caused by total hip replacement surgery. Bone loss is determined by measuring the patient's bone mineral density at several intervals after the operation. We have finished enrolling patients in this study. Patients were initially followed for two years, and we recently obtained approval to continue following patients in this study for an additional three years. This study was initiated by Dr. David Scott with funding from Procter & Gamble.

Dual Energy Xray Absorptiometry Analysis Of Five-Year Femoral Remodeling Of Uncemented Hip Prostheses (using dual energy x-ray absorptiometry to measure bone mineral density)

Patients who enrolled in this study were implanted with one of two different hip stems. The two stems had different designs and were made of different materials. Each patient's bone mineral density was measured at several intervals after surgery to investigate whether implantation of one of the stems resulted in less bone loss after total hip replacement surgery, as compared to the other. We have finished enrolling patients in this study. This study was initiated by Dr. David Scott in conjunction with Dr. William Jaffe at the University of Utah.

The Effects of a Low Modulus Composite Femoral Component on Adaptive Femoral Remodeling Post Total Hip Arthroplasty (THA) (using dual energy x-ray absorptiometry to measure bone mineral density)

This study compared bone loss caused by total hip replacement surgery in patients implanted with either a composite stem or a titanium stem. Bone mineral density was measured at several intervals after surgery using dual energy x-ray absorptiometry to determine the amount of bone loss. We have finished enrolling patients in this study. Patients are being followed for two years following total hip replacement surgery. This study was initiated by Dr. David Scott with funding from Zimmer.

Flexibility in Administration of Arixtra for Prevention of Symptomatic Venous Thromboembolism in Orthopedic Surgery

This study compared the efficacy of fondaparinux sodium (Arixtra) given either the day of surgery or the morning after surgery in preventing deep blood clots in patients after total knee replacement surgery. We have finished enrolling patients in this study. This study was sponsored by Organon Sanofi-Synthelabo.

Thromboprophylaxis with Low Molecular Weight Heparin (Fragmin) vs. Warfarin in Patients Undergoing Primary Total Knee Replacement. A Multicenter, Prospective, Randomized, Open-label Trial.

This study investigated the efficacy of dalteparin sodium (Fragmin) as compared to warfarin in preventing deep blood clots after total knee replacement surgery. We have finished enrolling patients in this study. This study was sponsored by Pfizer Pharmaceutical Company.

Randomized Multicenter Trial of a Ceramic-on-Metal Total Hip System

Most total hip replacements use a metal or ceramic "ball" attached to a metal stem and a metal socket with a plastic liner. In this study the hip replacement parts are a ceramic ball with metal shell insert or a metal ball with a metal shell insert. This study is being done to find out if the ceramic ball and metal liner hip implant will last as long or longer than the metal ball and metal liner hip implant. We have finished enrolling patients in this study but a two year follow-up is continuing. This study was sponsored by DePuy Orthopaedics Inc.

Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by Fentanyl HCl Transdermal System Versus Morphine IV Pump for Pain Management after Primary Unilateral Total Hip Replacement

Dr. Scott was one of a group of principal investigators who participated in this industry-sponsored study involving patients undergoing a total hip replacement. The purpose of this study was to determine if the study device was safe and effective in treating pain following surgery. This study device which contained fentanyl was worn on the skin like a patch and the patient could control dosing by pushing a button located on the device. The study device was compared to a standard treatment called morphine intravenous patient-controlled analgesia (IV PCA) pump. We have finished enrolling patients in this study. This study was sponsored by Ortho McNeil Pharmaceutical Inc.

Clinical Accuracy of Image-Free Computer-aided Navigation for Total Hip and Knee Replacement Surgery

The NaviPro Image-Free navigation system was designed to provide feedback to the surgeon on limb alignment and implant position during surgery. The primary objective of this study was to evaluate the accuracy of the NaviPro™ Image-Free™ navigation system in total hip and total knee replacement surgery and to further develop the NaviPro navigation software in a clinical environment to improve ease of use from the perspective of the surgeon and operating room staff. We have finished enrolling patients in this study. This study was sponsored by Kinamed, Inc.

A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75 mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran etexilate Administered Orally, Compared to Enoxaparin 30 mg twice a day subcutaneous for 12-15 days in Prevention of Venous Thromboembolism in Patients with Primary Elective Total Knee Replacement Surgery

Spokane Joint Replacement Center was one of 200 multi-national sites (including locations in the United States, Canada and Mexico) comparing two different doses of dabigatran etexilate (an oral anti-coagulant) and Lovenox® in a parallel group/double blind design. Dr David Scott is one of a group of principal investigators overseeing a portion of the 2,610 total patients who were divided into three groups receiving two different doses of study drug capsules and injections. We have finished enrolling patients in this study. This study was sponsored by Boehringer-Ingelheim pharmaceuticals.